US Stock MarketDetailed Quotes

RLMD Relmada Therapeutics

Watchlist
  • 3.020
  • +0.120+4.14%
Close Nov 29 13:00 ET
  • 3.000
  • -0.020-0.66%
Post 17:02 ET
91.13MMarket Cap-1055P/E (TTM)

Relmada Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Relmada Therapeutics Q3 2024 Earnings Date

Currency：USDNov 7, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
-0.64
-0.72
-0.08
Miss Est.
+12.33%
+1.37%
-12.52%
Analyst Rating
Strong Buy

Nov 30, 2024

Relmada Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2020/Q3-- / 0.000--
--2020/Q2-- / 0.000--
Nov 7, 20242024/Q30.000 / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
May 8, 20242024/Q10.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2020/Q3-- / 0.000--
--2020/Q2-- / 0.000--
Nov 7, 20242024/Q30.000 / 0.000--
Aug 7, 20242024/Q20.000 / 0.000--
May 8, 20242024/Q10.000 / 0.000--

Unlock Free Earnings Estimates

Relmada Therapeutics Earnings Reports

  • Relmada Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 7 16:10 ET

  • Relmada Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 7 16:10 ET

  • Relmada Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 8 16:13 ET

  • Relmada Therapeutics | 8-K: Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

    Mar 19 16:14 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Nov 30, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg

    No Data